The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
112109849 11210984 9 F 201412 20160922 20150623 20160927 EXP CA-ROCHE-1597342 ROCHE 57.23 YR M Y 0.00000 20160928 CN CA CA

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
112109849 11210984 1 PS XOLAIR OMALIZUMAB 1 Subcutaneous 150 MG, Q4 WEEKS U S0065E,S0002F,S0066B,S0068D,S0003C 103976 150 MG SOLUTION FOR INJECTION
112109849 11210984 2 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0065E,S0002F,S0066B,S0068D,S0003C 103976 SOLUTION FOR INJECTION
112109849 11210984 3 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0065E,S0002F,S0066B,S0068D,S0003C 103976 SOLUTION FOR INJECTION
112109849 11210984 4 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0065E,S0002F,S0066B,S0068D,S0003C 103976 SOLUTION FOR INJECTION
112109849 11210984 5 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0065E,S0002F,S0066B,S0068D,S0003C 103976 SOLUTION FOR INJECTION
112109849 11210984 6 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0065E,S0002F,S0066B,S0068D,S0003C 103976 SOLUTION FOR INJECTION
112109849 11210984 7 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0065E,S0002F,S0066B,S0068D,S0003C 103976 SOLUTION FOR INJECTION
112109849 11210984 8 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0065E,S0002F,S0066B,S0068D,S0003C 103976 SOLUTION FOR INJECTION
112109849 11210984 9 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0065E,S0002F,S0066B,S0068D,S0003C 103976 SOLUTION FOR INJECTION
112109849 11210984 10 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0065E,S0002F,S0066B,S0068D,S0003C 103976 SOLUTION FOR INJECTION
112109849 11210984 11 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0065E,S0002F,S0066B,S0068D,S0003C 103976 SOLUTION FOR INJECTION

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
112109849 11210984 1 Asthma

Outcome of event

Event ID CASEID OUTC COD
112109849 11210984 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
112109849 11210984 Body temperature decreased
112109849 11210984 Carcinoid tumour
112109849 11210984 Cough
112109849 11210984 Increased viscosity of upper respiratory secretion
112109849 11210984 Injection site erythema
112109849 11210984 Lower respiratory tract infection
112109849 11210984 Migraine
112109849 11210984 Pulmonary mycosis
112109849 11210984 Secretion discharge
112109849 11210984 Tumour marker increased

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
112109849 11210984 1 20141030 0
112109849 11210984 2 20150115 0
112109849 11210984 3 20150316 0
112109849 11210984 4 20150409 0
112109849 11210984 5 20150507 0
112109849 11210984 6 20160407 0
112109849 11210984 7 20160602 0
112109849 11210984 8 20160629 0
112109849 11210984 9 20160721 0
112109849 11210984 10 20160825 0
112109849 11210984 11 20160922 0